NervGen Pharma Corp (OTCMKTS:NGENF) Stock Rallies After Appointing a New CEO

Clinical stage biotech firm NervGen Pharma Corp (OTCMKTS:NGENF) is involved in the development of treatments meant for addressing damages suffered by the nervous system. Yesterday, the company announced that it appointed a new Chief Executive Officer and President in the form of Michael Kelly.

Trading Data

On Monday, NGENF stock gained 8.82% to $1.3820 with more than 40.40K shares, compared to its average volume of 32.84K shares. The stock moved within a range of $1.3200 – 1.3900 after opening trade at $1.3200.

NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer

The appointment went into effect yesterday. In addition to that, Kelly was also inducted into the board of directors of NervGen Pharma Corp. The Executive Chairman of the company Bill Ravdak spoke about the development as well. He noted that everyone at the company was excited at the prospect of Kelly joining in his positions and expressed his confidence that the new appointee would play a major role in the company’s future.

Ravdak also spoke about Kelly’s successful track record of leadership. It was further noted that Kelly commands experience spanning thirty years in the pharmaceutical industry and during that time he had been directly responsible for the creation and strengthening of a number of companies.

Kelly noted that he was excited about taking up his new leadership role at NervGen Pharma Corp and went on to add that the company was built on strong foundations with regards to the scientific side of things.